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REVIEW CURRENTOPINION Community-acquired pneumonia as an emergency
condition1070-5295 Copyright  2018 Woltea bCatia Cillo´niz , Cristina Dominedo` ,
Carolina Garcia-Vidalc, and Antoni TorresaPurpose of review
Despite the improvements in its management, community-acquired pneumonia (CAP) still exhibits high
global morbidity and mortality rates, especially in elderly patients. This review focuses on the most recent
findings on the epidemiology, cause, diagnosis and management of CAP.
Recent findings
There is consistent evidence that the trend in CAP mortality has declined over time. However, the mortality
of pneumococcal CAP has not changed in the last two decades, with an increase in the rate of
hospitalization and more severe forms of CAP. Streptococcus pneumoniae remains the most frequent cause
of CAP in all settings, age groups and regardless of comorbidities. However, the implementation of
molecular diagnostic tests in the last years has identified respiratory viruses as a common cause of CAP
too. The emergency of multidrug-resistance pathogens is a worldwide concern. An improvement in our
ability to promptly identify the causative cause of CAP is required in order to provide pathogen-directed
antibiotic therapy, improve antibiotic stewardship programs and implement appropriate vaccine strategies.
Summary
It is time to apply all the knowledge generated in the last decade in order to optimize the management
of CAP.
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Community-acquired pneumonia (CAP) is an emer-
gency condition with high morbidity and mortality
[1–3]. The incidence of CAP continues to rise, espe-
cially among elderly and immunocompromised
patients [3,4]. Pneumonia is the most common
infection leading to sepsis [5,6]. A recent study
reported the association of four comorbidities (dia-
betes mellitus, dementia, chronic heart failure and
coronary heart disease) on the development of sep-
sis in CAP patients [7]. Approximately 65%of elderly
patients hospitalized with CAP have two or more
comorbidities, thus experiencing a higher risk of
being affected by sepsis [4,8].
Severe CAP is frequently complicated by pulmo-
nary and extra-pulmonary complications, including
sepsis, septic shock, acute respiratory distress syn-
drome and acute cardiac events, thus resulting in a
significant increase of mortality and need for ICU
admission [4,9–13]. Although there is no general
consensus on its definition, the most accepted cri-
teria to address severe CAP are based on the 2007rs Kluwer Health, Inc. All rights reseInfectious Diseases Society of America/American
Thoracic Society consensus guidelines on the man-
agement of CAP in adults [1]. Severe CAP is defined
by the presence of two major criteria: severe acute
respiratory failure requiring invasive mechanical
ventilation and/or septic shock. Several minor crite-
ria requiring high-intensity monitoring and treat-
ment have been proposed for severe CAP diagnosis
too [14].rved. www.co-criticalcare.com
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KEY POINTS
 The incidence of CAP continues to rise, especially
among elderly and immunocompromised patients.
 Early recognition and management of severe CAP is of
pivotal importance in order to reduce mortality in
critically ill patients.
 Appropriate site of care decisions, based on clinical
assessment and supported by prognostic tools, can
improve patients’ outcomes.
 Risk factors for MDR pathogens should be recognized in
order to initiate an adequate empiric antibiotic therapy.
 Inflammatory biomarkers may be a complementary
prognostic tool for the management of CAP patients.
 There is lack of evidence regarding the utility of PCT in
antibiotic stewardship.
 Empiric antibiotic therapy should be based on
international and local guidelines, as this is
associated with improved outcomes.
 The use of corticosteroids should be considered in
severe CAP cases with high inflammatory response
(serum levels of C-reactive protein 15mg/dl).
Emergencies in critical careCAPmanagement in the emergency department
affects the final outcome of the infection. The fol-
lowing interventions have been related to improved
outcomes; prompt diagnosis through a chest X-ray
within the first 4h of presentation; early appropriate
antimicrobial therapy, covering multidrug resistant
pathogens when suspected; early identification of
patients requiring respiratory and hemodynamic
support and thus ICU admission; mortality risk
assessment using severity scores have been related
with improved outcomes [15].
This review summarizes the most recent find-
ings regarding CAP cause, risk factors, biomarkers
and therapy.WHY IS COMMUNITY-ACQUIRED
PNEUMONIA SEVERITY ASSESSMENT
IMPORTANT?
After the initial diagnosis of CAP, the biggest chal-
lenge in the emergency department is to promptly
recognize patients who might develop respiratory
failure and multiple organ dysfunctions. Patients
requiring mechanical ventilation or vasopressor
support should be admitted to ICU as soon as possi-
ble, as delays in ICU admission have been related to
worse outcomes [16–18].
Scoring systems such as the Pneumonia Severity
Index (PSI) [19] and the CURB-65 [14] (confusion,2 www.co-criticalcare.comurea, respiratory rate, blood pressure and age >65
years) predict short-term mortality and have been
developed to specifically support clinicians in the
decision to admit patients to the hospital; however,
their ability to predict the need for ICU admission
has not been demonstrated.
Recently, a Spanish study [20
&&
] compared the
clinical usefulness of the quick Sequential (Sepsis-
related) Organ Failure Assessment (qSOFA), the cri-
teria for Systemic Inflammatory Response Syndrome
(SIRS), CURB-65, CRB (confusion, respiratory rate
and blood pressure), modified Sepsis Organ Failure
Assessment (mSOFA) and PSI in a retrospective
cohort of 6874 patients with CAP. The authors
concluded that CRB and qSOFA outperformed SIRS,
whereas PSI was the best predictor of mortality.
The ATS/IDSA 2007major-minor criteria [1] and
the SMART-COP [21] (systolic blood pressure, multi-
lobar chest radiograph involvement, albumin, respi-
ratory rate, tachycardia, confusion, oxygenation
and arterial pH) are the scores most commonly used
to predict ICU admission.
The IDSA/ATS major (need for mechanical ven-
tilation or septic shock) and minor (respiratory rate
30breaths/min, PaO2/FiO2 ratio 250, multilobar
infiltrates, confusion or disorientation, blood urea
nitrogen20mg/dl, leukocyte count<4 109 cells/
l, platelets count <100  109 cells/l, temper-
ature<368C and hypotension requiring aggressive
fluid resuscitation) criteria have been proposed to
identify patients with severe CAP requiring ICU
admission. Minor criteria are easy to use and have
shown high specificity (91.7%) in predicting ICU
admission and the need for intensive respiratory or
vasopressor support [17,22]. Even in the absence of
major criteria, the presence of at least three minor
criteria has been associated with complications and
a high 30-day mortality risk [22,23].
SMART-COP [21] has been validated in several
studies [24,25]. It is based on eight parameters:
multilobar involvement (1 point), low systolic blood
pressure (2 points), high respiratory rate (1 point),
low albumin level (1 point), tachycardia (1 point),
confusion (1 point), poor oxygenation (age
adjusted, 2 points) and low arterial pH (2 points).
The Australian CAP Study (ACAPS) found that a
SMART-COP score of at least 3 points identified
the majority of patients who received intensive
respiratory or vasopressor support. Its accuracy
was higher than PSI classes IV and V and CURB-
65 group 3. SMART-COP was accurate both for
patients who were admitted to ICU directly from
the emergency department (sensitivity, 98%) and
for those who were initially admitted to the general
ward before their condition deteriorated (sensitiv-
ity, 84%).Volume 24  Number 00  Month 2018
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limitations. The ATS/IDSA criteria do not take into
account the criteria ‘age’. The SMART-COP score
cutoff for age is 50 years, thus limiting its applica-
bility in elderly patients. The omission of other
criteria such as COPD, immunosuppression, patient
dependency and other social factors limits the accu-
racy of the scores.
In conclusion, the experience and judgment of
clinicians in assessing patient severity remain vital
in the clinical management. We suggest to calculate
PSI or CURB65 after the initial diagnosis of CAP in
order to decide if the patient requires hospital
admission.
A second score (ATS/IDSA mayor and minor
criteria, SMART-COP, etc.) should be use to evaluate
the necessity for ICU admission.WHAT IS THE ROLE OF BIOMARKERS IN
COMMUNITY-ACQUIRED PNEUMONIA?
Biomarkers provide reliable information about the
host response to infection as well as the response to
pharmacological therapy. Unfortunately, the hetero-
genic immunological and inflammatory profiles of
CAP patients make the universal use of biomarkers
difficult [26
&
,27]. Biomarkers such as the C-reactive
protein (CRP), procalcitonin (PCT), lymphocytes, sol-
uble triggering receptor expressed on myeloid cells-1,
proadrenomedullin, copeptin and soluble form of
urokinase-type plasminogen activator receptor have
been studied and some of themvalidated [26
&
,28–34].
The biomarkersmostly used in the clinical practice are
CRP, PCT and more recently lymphocytes.BIOMARKER-GUIDED ANTIBIOTIC
THERAPY
CRP is a major acute phase protein synthesized by
hepatocytes. CRP is stimulated by interleukin 6 and
8 (IL-6 and IL-8), mainly produced by macrophages
in response to any type of inflammation, including
bacterial and viral infection. The protein release
starts 4–6h after the beginning of the inflamma-
tion, with a peak around 36–48h. The plasma half-
life is about 7–10h. CRP is not specific for the
diagnosis of pneumonia as its levels can be elevated
in other clinical conditions such as neoplasia or
autoimmune diseases [35].
PCT is a calcitonin precursor peptide usually
synthesized in the thyroid gland. It increases during
inflammatory and infectious diseases. In healthy
individuals, it is almost undetectable or lower than
0.05ng/ml. PCT has been demonstrated to be useful
to differentiate pneumonia from other clinical con-
ditions [35].1070-5295 Copyright  2018 Wolters Kluwer Health, Inc. All rights reseRecently, in a multicenter prospective surveil-
lance study of 1735 adults hospitalized with CAP
[36
&
], no PCT threshold was found to specifically
discriminate between viral and bacterial pathogens.
However, higher values of PCT strongly correlated
with an increased probability of bacterial pathogens,
particularly typical bacteria (Fig. 1).
Interestingly, a recent multicenter trial con-
ducted in 14 hospitals from United States investi-
gated the effect of PCT-guided antibiotic use on the
treatment of suspected lower respiratory tract infec-
tions [37]. Data of 1656 patients (826 randomly
assigned to the PCT group and 830 to the usual-care
group) were analyzed. In both groups, PCT-level tier
was associated with the decision to prescribe anti-
biotics in the emergency department. There was no
significant difference between the two groups in
either antibiotic-days or the proportion of adverse
outcomes within 30 days.
Similarly, Chu et al. [38] investigated the PCT
use in critically ill patients with sepsis in a real-world
setting where the main site of infection was pneu-
monia (accounting for 35% of the study popula-
tion). PCT use did not improve antibiotic use or
antibiotic-associated outcomes on average; con-
versely, PCT use was associated with an increased
incidence of Clostridium difficile infections.
The results of the two above mentioned studies
may be interpreted considering the partially under-
stood PCT biology and physiology and the variabil-
ity of PCT levels in some situations such as acute
kidney injury or renal replacement therapies. These
results contrast with the findings of a previous sys-
tematic review and meta-analysis [39
&
]. PCT use to
guide initiation and duration of antibiotic treat-
ment in acute respiratory tract infections resulted
in lower risk ofmortality, lower antibiotic consump-
tion and lower risk of antibiotic-related side-effects.
Despite the promising value of CRP and PCT,
there are still several limitations for their use in the
daily clinical practice. Clinical judgment, severity
scores and biomarkers should help in the diagnosis
of CAP and in the beginning of the empiric
antibiotic therapy.BIOMARKERS FOR COMMUNITY-
ACQUIRED PNEUMONIA PROGNOSIS
Several studies reported that biomarkers can also be
used to predict clinical outcomes, complications
such as bacteremia and mortality in patients
affected by CAP [29,35].
The recent study by McCluskey et al. [40
&
] inves-
tigating the use of PCT to predict mortality, ICU
admission and bacteremia in 317 patients with
pneumonia (191 CAP and 126 HCAP) reported thatrved. www.co-criticalcare.com 3
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FIGURE 1. Procalcitonin: microbial cause and prognostic outcomes in CAP. CAP, community-acquired pneumonia.
Emergencies in critical careserial PCT measurements improve the performance
of clinical scores (PSI) to predict bacteremia and the
necessity for ICU-level care nevertheless without
predicting mortality.
Zhou et al. [29] investigated the risk stratifica-
tion and prognostic prediction value of PCT and
clinical severity scores (CURB65, PSI, SOFA and
qSOFA) in patients with CAP admitted at the emer-
gency department. The authors reported that PCT
was a predictor of severe CAP. Compared to other
combinations, the combination of PCT and SOFA
score achieved the highest superiority in predicting
not only severe CAP but also 28-day mortality.
A study from South Korea investigated the abil-
ity of CRP, PCT and various clinical risk scales (PSI,
ATS/IDSA and CURB65) to predict 28-day mortality
in CAP patients. PCT was a predictor of short-term
mortality inCAP patients. Consequently, the author
suggested that the use of CRP and/or PCT could
significantly improve the performance of the PSI
and the IDAS/ATS score [41].
Recently, some studies examined the role of
peripheral blood lymphocytes count as prognostic
predictors in CAP. A study from Spain [26
&
] investi-
gated the association between neutrophil and lym-
phocyte counts and the mortality risk at 30-days
post hospital admission in CAP patients. The pres-
ence of lymphopenia conferred an increased risk of
mortality (‘lymphopenic CAP profile’); furthermore,4 www.co-criticalcare.comthe addition of the lymphocyte count to the CURB-
65 improved the ability to predict 30-day mortality.
Interestingly, a study from China [42] found
that the combination of PO2 /FiO2 and lymphocyte
counts predicted mortality and ICU admission in
hospitalized patients with influenza pneumonia.
Particularly, when PO2 /FiO2 is less than 250 or
peripheral blood lymphocyte count is less than
0.8  109 /l, great attention should be paid for the
possibility of severe influenza pneumonia.
Some studies proposed the neutrophil to lym-
phocyte ratio (NLR) as simple and inexpensive indi-
cators of systemic inflammation and infection. An
Italian study [43] explored the performance of the
NLR to predict prognosis in a cohort of 195 elderly
adults with CAP. NLR predicted 30-day mortality
and performed better than PSI, CURB65, CRP and
white cell count to predict prognosis in the studied
population. The authors recommended early dis-
charge for CAP patients with NLR less than 11.12,
short-term in-hospital care for CAP patients with
NLR between 11.12 and 13.4, middle-term hospital-
ization for CAP patients with NLR between 13.4 and
28.3 and ICU admission for those with NLR at
least 28.3.
The role of lymphocytes has also been explored
in a recent Spain study in 160 HIV patients with CAP
[44]. The authors reported that red blood cell distri-
bution and lymphocytes were the most usefulVolume 24  Number 00  Month 2018
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requiring ICU admission.THE IMPORTANCE TO IMPLEMENT A
POINT-OF-CARE TESTING IN COMMUNITY-
ACQUIRED PNEUMONIA
Point-of-care testing (POCT) tools refer to etiologic
test methods (e.g. viral respiratory panels), which
can be used very close to the patient’s treatment site,
thus allowing faster CAP etiological diagnosis, early
antimicrobial treatment and prompt therapy adjust-
ments. An RCT by Brendish et al. [45
&&
] investigated
the effect of routine POCT on a broad range of
clinical outcomes (including antibiotic use) in
adults presenting to the acute medical unit or to
the emergency department with acute respiratory
illnesses. Patients were allocated in the POCT group
(a rapid molecular test for 15 respiratory viruses was
performed with results available in 2–3h) or in the
routine clinical care group. POCT did not reduce the
proportion of patients treated with antibiotics. The
authors explained that the result could be related to
the administration of antibiotics, before test results
were available, to a great proportion of patients in
the POCT group. Interestingly, 91% of patients in
the POCT group diagnosed with influenza virus
received neuraminidase inhibitors compared with
65% of patients in the control group. The prompt
initiation of neuraminidase inhibitor therapy in
patients with influenza virus could have improved
survival and reduced complications such as bacterial
pneumonia. Other potential benefits of POCT in
CAP caused by respiratory viruses included reduc-
tion of unnecessary antibiotic use, improved use of
directed antiviral therapy for influenza virus, early
identification of patients requiring isolation and
reduction in hospital length of stay.WHAT ARE THE MAIN RISK FACTORS FOR
MULTIDRUG-RESISTANT PATHOGENS?
Although several bacteria and respiratory viruses are
responsible of CAP, Streptococcus pneumoniae (Pneu-
mococcus) remains the most common pathogen
that causes it. Hoverer, approximately 6% of CAPs
are caused bymultidrug-resistant (MDR) pathogens,
with Pseudomonas aeruginosa and methicillin-resis-
tant Staphylococcus aureus (MRSA) being the most
frequently reported [46,47].
Because the antibiotic therapy for P. aeruginosa
and MRSA is different from usual CAP therapy, it is
important to recognize risk factors associated with
these pathogens.
Risk factors for P. aeruginosa include structural
lung diseases (bronchiectasis and COPD), nursing1070-5295 Copyright  2018 Wolters Kluwer Health, Inc. All rights resehome residence, C-reactive protein less than
12.35mg/dl, prior use of oral steroids, antibiotic
therapy within the last 90 days and malnutrition;
chronic P. aeruginosa colonization in patients with
bronchiectasis and COPD can be an important pre-
liminary step to pneumonia too.
Recently, the study by Cillo´niz et al. [48] in a
cohort of 2023 patientswithCAP reported that 4%of
caseswere caused byP. aeruginosa.Risk factors for this
pathogenweremale sex, chronic respiratory diseases,
C-reactive protein less than 12.35mg/dl and PSI risk
class IV–V. The only risk factor forMDR P. aeruginosa
CAP was prior antibiotic treatment.
A Spanish study [49] analyzing 1519 patients
with CAP found that PES pathogens (P. aeruginosa,
Enterobacteriaceae extended spectrum b-lactamase-pos-
itive and MRSA) caused CAP in 6% of patients and
were associated with an increased risk of 30-day
mortality. The authors proposed a score to assess
the risk of pneumonia because of PES pathogens
(Fig. 2).
The risk for MRSA is higher in patients with
previous MRSA colonization, end-stage renal dis-
ease, contact sport participants, injection drug users,
those living in crowded conditions, men who have
sex with men and prisoners. Other risk factors
include underlying lung diseases, recent influenza
infection, previous antibiotic use, hospitalization in
the previous 90 days and need for ICU admission
[50,51].WHAT IS THE RECOMMENDED EMPIRIC
ANTIBIOTIC THERAPY IN SEVERE
COMMUNITY-ACQUIRED PNEUMONIA?
Current international guidelines recommend the
use of a macrolide or a respiratory fluoroquinolone
in combination with a b-lactam for severe CAP
[1,52]. Coverage for P. aeruginosa and MRSA should
be administered depending on risk factors. How-
ever, there are not conclusive data regarding the
superiority of b-lactam and macrolide (BL-M) com-
pared to b-lactam and fluoroquinolones (BL-F) in
the treatment of severe CAP.
A recent systematic review and meta-analysis
[53
&&
] was performed on patients with severe CAP.
Compared to patients treated by BL-F, patients
receiving BL-M were discharged from hospital
approximately 3 days earlier. However, ICU length
of stay did not differ between the two groups. The
overall mortality significantly differs between the
two groups, with rates of 19 and 27% for the BL-M
and the BL-F groups, respectively.
We recommend to follow the current interna-
tional guidelines for the empiric therapy of severe
CAP [1].rved. www.co-criticalcare.com 5
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FIGURE 2. PES score.
Emergencies in critical careADJUNCTIVE THERAPIES IN COMMUNITY-
ACQUIRED PNEUMONIA
During the last decade, there has been an increasing
interest in the protective role of adjunctive anti-
inflammatory therapies (mainly corticosteroids) in
CAP, especially in severe cases.CORTICOSTEROIDS IN SEVERE
COMMUNITY-ACQUIRED PNEUMONIA
In 2015, an interesting randomized study found that
in patients with severe CAP (according to ATS/IDSA
criteria) and a high inflammatory response (initial
levels of CRP >15mg/dl), the use of low doses of
corticosteroids compared with placebo decreased
treatment failure with no difference in mortality
[54] (Fig. 3).
A 2017 update [55] of a previously published
review assessed the efficacy and safety of systemic
corticosteroids, given as adjunct to antibiotic ther-
apy, compared to placebo or no corticosteroids in
the treatment of pneumonia. Corticosteroids
reduced mortality and morbidity in adults with
severe CAP; the number needed to treat for an
additional beneficial outcome was 18 patients
(95% CI 12–49) to prevent one death. Corticoste-
roids, however, reducedmorbidity but notmortality6 www.co-criticalcare.comin adults and children with nonsevere CAP. Corti-
costeroid therapy was associated with more adverse
events, especially hyperglycemia, but the harms did
not seem to outweigh the benefits.
More recently, a systematic review analyzed all
data from RCTs assessing the role of adjunctive
corticosteroids in CAP [56]. The time to clinical
stability and the hospital length of stay were
reduced by approximately 1 day with corticoste-
roids. No significant effect on overall mortality
was described. However, the authors found an
increased risk for CAP-related rehospitalization
and hyperglycemia with steroid treatment.
In conclusion, we recommend to use corticoste-
roids in the treatment of severe CAP cases with high
inflammatory response (serum levels of C-reactive
protein 15mg/dl) (Fig. 3).CORTICOSTEROIDS IN INFLUENZA
PNEUMONIA
A secondary analysis of a prospective cohort study
investigated the clinical predictors associated with
corticosteroids administration in critically ill
patients with confirmed influenza pneumonia
admitted to 148 ICUs in Spain [57
&
]. The adminis-
tration of corticosteroids in patients with severeVolume 24  Number 00  Month 2018
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FIGURE 3. Algorithm of corticosteroids administration in severe CAP. CAP, community-acquired pneumonia.
Community-acquired pneumonia Cillo´niz et al.influenza pneumonia was associated with increased
ICUmortality. Consequently, the authors suggested
not using corticosteroids as a coadjuvant therapy in
patients with influenza pneumonia.CORTICOSTEROIDS IN SEPTIC SHOCK
Two recent RCTs [10,11]evaluated the role of hydro-
cortisone in patients with septic shock, reporting
conflicting results. In the ADRENAL trial [10],
patients with septic shock undergoing mechanical
ventilation were randomized to receive hydrocorti-
sone (at a dose of 200mg per day) or placebo for
7 days or until death or discharge from the ICU. The
continuous infusion of hydrocortisone in this pop-
ulation did not result in a lower 90-day mortality
compared to placebo. The APROCCHSS trial [11]
evaluated the effect of hydrocortisone-and-fludro-
cortisone compared to placebo in adult patients
with septic shock. The authors reported that 90-
day all-cause mortality was lower among patients
receiving hydrocortisone and fludrocortisone than
among those receiving placebo.1070-5295 Copyright  2018 Wolters Kluwer Health, Inc. All rights reseCONCLUSION
CAP remains a significant cause of morbidity, mortal-
ity and health cost globally, despite the implementa-
tion of important measures that improve its
management. The inclusion of biomarkers (indepen-
dently or in combination) with severity scores will
help to improve the early diagnosis of CAP, the pre-
dictionof its clinical severity and the early recognition
of patients requiring ICUadmission. Early appropriate
empiric antibiotic therapy can increase survival and
improve clinical outcomes, especially in severe CAP.
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